Free live webinar on 'Copy Number Detection in Inherited Disorders and Somatic Cancer' on 25 June, 2015
Session 1: 25 June; 2:00 PM IST (1:30 AM PDT)
Session 2: 25 June; 9:30 PM IST (9:00 AM PDT)
Register for free! http://www.strand-ngs.com/webinar_registration
Webinar Abstract:
Copy number variants constitute a significant fraction of genomic alterations responsible for cancer and various inherited disorders. In a clinical setting, performing focused NGS testing based on a panel of relevant genes is both economical and provides faster results. Thus the ability to detect CNVs from gene panel based NGS tests increases the diagnostic yield significantly. In this webinar, we will present few clinical case studies to demonstrate the new CNV analysis workflow in Strand NGS that enables researchers to detect and visualize copy number changes ranging from single exon to chromosome level events.
About Speaker:
Dr. Smita Agrawal, Senior Scientist, Strand Life Sciences, has over 14 years of research experience applying analytical methods to biological problems in the fields of neuroscience, stem cell biology, immunology and genetics. Smita has a PhD in Chemical Engineering from the University of California, Berkeley and has experience working as a post-doctoral scholar in the division of Human Genetics at the University of Minnesota, and as a researcher in the early discovery division of Genentech Inc. At Strand, she heads the clinical data analysis group and also guides the product definition of StrandOmics, Strand’s clinical genomics interpretation and reporting software.
For more information, please write to sales[at]strandngs.com OR strandlive[at]strandls.com
-
NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...10-30-2026, 06:46 AM -
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM